Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003437-26
    Sponsor's Protocol Code Number:CO-1686-020
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-02-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-003437-26
    A.3Full title of the trial
    TIGER-3: A Phase 3, Open-Label, Multicenter, Randomized Study of Oral
    Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic
    Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer
    (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase
    Inhibitor (TKI) and Platinum-doublet Chemotherapy
    TIGER-3: studio randomizzato, multicentrico, in aperto, di fase 3 su rociletinib orale (CO 1686) in monoterapia rispetto alla chemioterapia citotossica ad agente singolo in pazienti con tumore al polmone non a piccole cellule (NSCLC) con mutazione dell'EGFR, dopo l'insuccesso di almeno una terapia a base di un inibitore della tirosina chinasi (TKI) mirato per EGFR e di una chemioterapia con due farmaci contenente platino
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 clinical study to evaluate the safety and efficacy of the study
    medication Rociletinib compared to pemetrexed, gemcitabine, docetaxel, or
    paclitaxel in subjects with Non-Small Cell Lung Cancer
    Studio clinico di fase 3 per valutare la sicurezza e l'efficacia del farmaco Rociletinib rispetto a pemetrexed,gemcitabina, docetaxel o paclitaxel in soggetti con tumore al polmone non a piccole cellule.
    A.3.2Name or abbreviated title of the trial where available
    TIGER-3
    TIGER-3
    A.4.1Sponsor's protocol code numberCO-1686-020
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCLOVIS ONCOLOGY, INC
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportClovis Oncology, Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationClovis Oncology UK Ltd
    B.5.2Functional name of contact pointDr Lindsey Rolfe
    B.5.3 Address:
    B.5.3.1Street AddressSheraton House, Castle Park
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeCB3 0AX
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number00441223370037
    B.5.5Fax number00000000000000
    B.5.6E-mailinfo@clovisoncology.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRociletinib
    D.3.2Product code CO-1686
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1446700-26-0
    D.3.9.2Current sponsor codeCO-1686
    D.3.9.3Other descriptive nameRociletinib
    D.3.9.4EV Substance CodeSUB126980
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number125
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRociletinib
    D.3.2Product code CO-1686
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1446700-26-0
    D.3.9.2Current sponsor codeCO-1686
    D.3.9.3Other descriptive nameRociletinib
    D.3.9.4EV Substance CodeSUB126980
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name DOCETAXEL HOSPIRA - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2ML
    D.2.1.1.2Name of the Marketing Authorisation holderHOSPIRA ITALIA S.R.L.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 114977-28-5
    D.3.9.2Current sponsor codeNon applicabile
    D.3.9.3Other descriptive nameDocetaxel
    D.3.9.4EV Substance CodeSUB12492MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name GEMCITABINA SUN - 200 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 10 ML
    D.2.1.1.2Name of the Marketing Authorisation holderSUN PHARMACEUTICAL INDUSTRIES (EUROPE) B.V.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 95058-81-4
    D.3.9.2Current sponsor codenon applicabile
    D.3.9.4EV Substance CodeSUB02324MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name PACLITAXEL ESP PHARMA - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO VETRO DA 30 MG/5 ML
    D.2.1.1.2Name of the Marketing Authorisation holderESP PHARMA LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 33069-62-4
    D.3.9.2Current sponsor codenon applicabile
    D.3.9.3Other descriptive namePACLITAXEL
    D.3.9.4EV Substance CodeSUB09583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number6
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO
    D.2.1.1.2Name of the Marketing Authorisation holderELI LILLY NEDERLAND BV
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 137281-23-3
    D.3.9.2Current sponsor codePEMETREXED
    D.3.9.4EV Substance CodeSUB09655MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name DOCETAXEL HOSPIRA - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2ML
    D.2.1.1.2Name of the Marketing Authorisation holderHOSPIRA ITALIA S.R.L.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 114977-28-5
    D.3.9.2Current sponsor codenon applicabile
    D.3.9.3Other descriptive nameDOCETAXEL
    D.3.9.4EV Substance CodeSUB12492MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with EGFR mutant Non-Small Cell Lung Cancer who have failed
    at least 1 previous EGFR-directed TKI and 1 line of platinum‑containing
    doublet chemotherapy
    pazienti con NSCLC con mutazione dell'EGRF, dopo l'insuccesso di almeno 1 terapia a base di un inibitore della tirosina chinasi (TKI) mirato per EGFR e di almeno 1 linea di chemioterapia con due farmaci contenente platino.
    E.1.1.1Medical condition in easily understood language
    Third and later line Treatment of Patients with EGFR-Mutant Advanced
    Non-Small Cell Lung Cancer
    terza e tardiva linea di trattamento di pazienti con EGFR-Mutata avanzata del cancro al polmone non a piccole cellule
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10029514
    E.1.2Term Non-small cell lung cancer NOS
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the anti-tumor efficacy of oral single-agent rociletinib, as
    measured by investigator assessment of the PFS, with that of singleagent
    cytotoxic chemotherapy in patients with EGFR-mutated,
    advanced/metastatic NSCLC after failure of at least 1 previous EGFRdirected
    TKI and at least 1 line of platinum-containing doublet chemotherapy
    Confrontare l'efficacia antitumorale di rociletinib come agente singolo, misurata come valutazione da parte dello sperimentatore della sopravvivenza libera da progressione (Progression-Free Survival, PFS), con quella della chemioterapia citotossica ad agente singolo nei pazienti con NSCLC avanzato/metastatico con mutazione dell'EGRF, dopo l'insuccesso di almeno 1 terapia a base di un inibitore della tirosina chinasi (TKI) mirato per EGFR e di almeno 1 linea di chemioterapia con due farmaci contenente platino.
    E.2.2Secondary objectives of the trial
    To compare secondary measures of clinical efficacy (ORR, DR, DCR and
    OS) between patients randomized to rociletinib or single-agent cytotoxic
    chemotherapy
    • To compare the safety and tolerability of rociletinib with that of singleagent
    cytotoxic chemotherapy
    • To determine PK of rociletinib using population PK (POPPK) methods
    and explore correlations between PK, exposure, response, and/or safety
    findings in patients randomized to rociletinib
    • Confrontare le misure secondarie di efficacia clinica (tasso di controllo della malattia [Disease Control Rate, DCR], durata della risposta [Duration of Response, DR], tasso di risposta obiettiva [Objective Response Rate, ORR] e sopravvivenza complessiva [Overall Survival, OS]) fra i pazienti randomizzati per rociletinib o per la chemioterapia citotossica ad agente singolo
    • Confrontare sicurezza e tollerabilità di rociletinib con quelle di una chemioterapia citotossica ad agente singolo
    • Determinare la farmacocinetica (Pharmacokinetics, PK) di rociletinib utilizzando i metodi della popolazione PK (POPPK) ed esaminare le correlazioni fra PK, esposizione, risposta e/o risultati di sicurezza nei pazienti randomizzati a rociletinib
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Histologically or cytologically confirmed metastatic or unresectable
    locally advanced NSCLC with radiological progression on the most recent
    therapy received
    2. Documented evidence of a tumor with 1 or more EGFR activating
    mutations excluding exon 20 insertion
    3. Disease progression confirmed by radiological assessment while
    receiving treatment with single-agent EGFR-TKI
    4. Multiple lines of prior treatment are permitted but patients must have
    received at least 1 line of treatment with an EGFR TKI and a platinumcontaining
    doublet chemotherapy 5. Have undergone a biopsy of either primary or metastatic tumor tissue
    within 60 days prior to start of treatment and have tissue available to
    send to sponsor laboratory or are able to undergo a biopsy during
    Screening and provide tissue to
    sponsor laboratory
    6. Measureable disease according to RECIST Version 1.1
    7. Life expectancy of at least 3 months
    8. ECOG performance status of 0 to 1
    9. Age ≥ 18 years (in certain territories, the minimum age requirement
    may be higher e.g., age ≥ 20 years in Japan and Taiwan; age ≥ 21 years
    in Singapore)
    10. Patients should have recovered to National Cancer Institute (NCI)
    Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1
    from any significant chemotherapy-related toxicities
    11. Adequate hematological and biological function, confirmed by local
    laboratory value se.g. Bone Marrow Function, Hepatic Function, Renal
    function and Electrolyte within normal range
    12. Written consent on an Institutional Review Board
    (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study specific evaluation
    1. NSCLC metastatico o non resecabile localmente avanzato, confermato per via istologica o citologica, con progressione radiologica durante la terapia ricevuta più di recente
    2. Evidenza documentata di un tumore con 1 o più mutazioni attivanti EGFR, esclusa l'inserzione dell'esone 20
    3.Progressione della malattia confermata da valutazione radiologica durante il trattamento con EGFR-TKI ad agente singolo
    4. Sono consentite più linee di trattamento precedenti ma i pazienti devono aver ricevutoalmeno 1 linea di trattamento precedente con una terapia EGFR-TKI ad agente singolo
    o una chemioterapia con due farmaci a base di platino
    5. Essere stato sottoposto a biopsia del tumore primario o delle metastasi nei 60 giorni precedenti l'inizio del trattamento e disponibilità di tessuto da inviare al laboratorio dello sponsor o possibilità di sottoporsi a biopsia durante lo screening per fornire il tessuto al laboratorio dello sponsor.
    6. Malattia misurabile in conformità con RECIST Versione 1.1
    7. Aspettativa di vita di almeno 3 mesi
    8. Stato di prestazione ECOG di 0 o 1
    9. Età ³ 18 anni (in alcune aree geografiche l'età minima richiesta può essere superiore, ad es. ³ 20 anni in Giappone e a Taiwan, ³ 21 anni a Singapore)
    10. I pazienti devono essersi ristabiliti al livello indicato dal National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 (Criteri terminologici comuni per gli eventi avversi di grado ≤ 1) da qualsiasi tossicità significativa associata alla chemioterapia
    11. Funzioni ematologiche e biologiche adeguate, confermate dai seguenti valori delle analisi presso il laboratorio locale:
    Funzione del midollo osseo
    Funzione epatica, funzione renale ed elettroliti con valori normale.
    12.Consenso scritto su un modulo di consenso informato ICF, approvato da un Comitato Etico indipendente o una Commissione di revisione dell'istituzione, prima di qualsiasi valutazione specifica dello studio
    E.4Principal exclusion criteria
    1. Any other malignancy associated with a high mortality risk within the
    next 5 years and for which the patients may be (but not necessarily)
    currently receiving treatment
    2. Known pre-existing interstitial lung disease
    3. Tumor small cell transformation by local assessment, irrespective of
    presence of T790M+ component
    4. Patients with leptomeningeal carcinomatosis are excluded.
    5. Patients who are currently receiving treatment with any medications
    that have the potential to prolong the QT interval and that treatment
    cannot be either discontinued or switched to a different medication
    (known to have no effect on QT) before starting protocol-specified
    treatment
    6. Prior treatment with rociletinib, or other drugs that target T790M+
    mutant EGFR with sparing of WT-EGFR including but not limited to
    AZD9291, HM61713, and TAS-121
    7. Any contraindications for therapy with pemetrexed, paclitaxel,
    gemcitabine or docetaxel unless a contraindication with respect to one
    of these drugs will not affect the use of any of the others as a
    comparator to rociletinib
    8. Cardiac abnormalities or history
    9. Non-study related surgical procedures ≤ 7 days prior to
    randomization. In all cases, the patient must be sufficiently recovered
    and stable before treatment administration.
    10. Females who are pregnant or breastfeeding
    11. Refusal to use adequate contraception for fertile patients (females
    and males) while on treatment and for 6 months after the last dose of
    study treatment (rociletinib and chemotherapy irrespective of single
    cytotoxic agent used)
    12. Presence of any serious or unstable concomitant systemic disorder
    incompatible with the clinical study (e.g., substance abuse, uncontrolled
    intercurrent illness including active infection, arterial thrombosis, and
    symptomatic pulmonary embolism)
    13. Any other reason the investigator considers the patient should not participate in the study
    1. Qualsiasi altro tumore maligno associato a un elevato rischio di mortalità nei 5 anni successivi per il quale il paziente può ricevere al momento un trattamento (ma non necessariamente)
    2. Malattia interstiziale polmonare nota pre-esistente
    3. Trasformazione delle piccole cellule tumorali rilevata dalla valutazione locale, indipendentemente dalla presenza del componente T790M+
    4. I pazienti con carcinomatosi leptomeningea sono esclusi
    5. Pazienti che attualmente ricevono un trattamento con farmaci che possono prolungare l'intervallo QT e non possono essere sospesi o per i quali non risulta possibile passare ad altri farmaci (noti per non avere effetti sul QT) prima di iniziare il trattamento specificato dal protocollo
    6. Trattamento precedente con rociletinib o altri farmaci che hanno come bersaglio EGFR mutante T790M+ e non hanno effetto sull'EGFR WT, compresi, a titolo esemplificativo, AZD9291, HM61713 e TAS-121
    7. Eventuali controindicazioni per la terapia con pemetrexed, paclitaxel, gemcitabina o docetaxel, a meno che una controindicazione per uno di questi farmaci non influenzi l'uso di uno degli altri farmaci come comparatore di rociletinib
    8. Qualsiasi anamnesi o anomalie cardiache
    9. Procedure chirurgiche non associate allo studio ≤ 7 giorni prima della randomizzazione. In tutti i casi il paziente si deve essere sufficientemente ripreso e deve risultare in condizioni stabili prima della somministrazione del trattamento.
    10. Donne in gravidanza o in allattamento (al seno).
    11. Soggetti fertili (femmine e maschi) che si rifiutano di utilizzare metodi contraccettivi adeguati durante il trattamento e per 6 mesi dopo l'ultima dose di trattamento dello studio (rociletinib e chemioterapia, indipendentemente dall'agente citotossico utilizzato)
    12. Presenza di eventuali disturbi sistemici concomitanti gravi o instabili, incompatibili con lo studio clinico (ad es. abuso di sostanze, patologia intercorrente non controllata compresi diabete non controllato, infezioni attive, trombosi arteriosa ed embolia polmonare sintomatica)
    13. Qualsiasi altro motivo per il quale lo sperimentatore consideri il paziente non idoneo a partecipare allo studio.
    E.5 End points
    E.5.1Primary end point(s)
    Progression-free survival (PFS) according to RECIST Version 1.1 as
    determined by investigator assessment (invPFS)
    PFS in conformità con RECIST Versione 1.111, determinata dalla valutazione dello sperimentatore (invPFS)
    E.5.1.1Timepoint(s) of evaluation of this end point
    From start of treatment until it is clear that no further clinical benefit can
    be achieved.
    Dall'inizio del trattamento fino a quando è chiaro che nessun ulteriore beneficio clinico può
    essere realizzato.
    E.5.2Secondary end point(s)
    ORR, DR, and DCR according to RECIST Version 1.1 as determined by
    investigator assessment
    • OS
    • Treatment-emergent AEs, laboratory abnormalities, and ECG
    abnormalities
    • Plasma PK parameters for rociletinib based on sparse sampling
    •ORR, DR e DCR in conformità con RECIST Versione 1.1, determinati dalla valutazione dello sperimentatore
    • OS
    • Eventi avversi (AE) derivanti dal trattamento, anomalie di laboratorio e anomalie dell'elettrocardiogramma (ECG)
    • Parametri PK plasmatici per rociletinib sulla base di un campionamento ridotto
    E.5.2.1Timepoint(s) of evaluation of this end point
    From start of treatment until it is clear that no further clinical benefit can be achieved.
    Dall'inizio del trattamento fino a quando è chiaro che nessun ulteriore beneficio clinico può
    essere realizzato.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    pemetrexed, gemcitabina, docetaxel, o paclitaxel
    pemetrexed, gemcitabine, docetaxel, or paclitaxel
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA50
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    France
    Germany
    Italy
    Korea, Republic of
    Netherlands
    Spain
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The trial will be completed when all enrolled patients have discontinued
    treatment in this protocol and completed the End-of-Treatment followup
    Visit.
    lo studio sarà completato quando tutti i pazienti arruolati avranno interotto lo studio e completato la visita di follow up di fine trattamento
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 175
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 425
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state55
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After the End of treatment the patients will return to their normal SOC
    medication.
    Dopo il termine di trattamento i pazienti ritorneranno alla loro medicazione standard di cura
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-05-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-03-20
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:23:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA